Skip to main content

COVID 19 Updates from RheumNow

Best of 2020: Rheumatic Disease Drugs and COVID-19

Editor's note: This article originally appeared March 17, 2020, and is being shared again this week as a "Best of 2020" article. Enjoy!

Best of 2020: The Nine Lives of Hydroxychloroquine (Updated)

Editor's note: This article originally appeared May 18, 2020, and is being shared again as a "Best of 2020" article as we wrap up this year. 

ACIP Recommendations for Pfizer-BioNTech COVID-19 Vaccine Use (including Special Populations)

CDC/MMWR

Following the FDA issuance of an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for the prevention of COVID-19 in persons aged ≥16 years. 

COVID-19 as a Leading Cause of Death in the USA

The exponential rise in deaths from the coronavirus (COVID-19) in the last several months is put into perspective by JAMA Viewpoint article noting that current US death rates of > 3000 per day from COVID-19 is greater than that seen in one day on September 11, 2001 (9/11 attacks, clai

COVID Risks in Systemic Autoimmune Patients

There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture. 

RheumNow Podcast – Stop These COVID Mistakes (12.11.20)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Rheumatic Disease and COVID-19: Who Is at Risk?

MedPage Today

Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.

ACIP Recommendations for Pfizer Vaccine Candidate

The CDC advisory panel, ACIP, has voted and declared that the first wave of vaccines should go to the front line healthcare workers and elderly residents in long term care facilities as part of Phase1a.

My Experience as a COVID19 Vaccine Trial Participant

I have been an investigator for many clinical rheumatology studies over the past two decades but have never been a study subject until now. I wanted to document my experience and allay any fears about the vaccine or the clinical trials process.

Answering questions on how COVID-19 affects rheumatic patients

As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.

Social

#Bestof2020 Plaquenil Does Not Protect Lupus Patients from COVID-19 https://t.co/R5S7phlqYb https://t.co/HDlDfE98RQ
Dr. John Cush RheumNow( View Tweet)
2 weeks ago
NEJM: Actemra Studied in COVID pneumonia and shown to improve outcomes (mech ventilation or death ;12 vs 19.3%) but did not improve survival (10.4 vs 8.6%). 389 hospitalized pts randomized 2:1 to get 2 IV doses Actemra +SOC vs SOC alone https://t.co/BdslXFXOYD

Dr. John Cush RheumNow( View Tweet)

2 weeks ago
#Bestof2020 My Experience as a COVID19 Vaccine Trial Participant https://t.co/bMJoTR5mgv https://t.co/7QJqhXhhCX
Dr. John Cush RheumNow( View Tweet)
2 weeks 6 days ago
Race/ethnicity Associated with Poor Outcomes in Rheum Patients with COVID-19 : Dr. Dey ( @DrMiniDey) #acr20 https://t.co/ecenB2i5At https://t.co/q8QJ5CxqBF
Dr. John Cush RheumNow( View Tweet)
3 weeks ago
COVID Vaccine Q & A - Dr Kevin Winthrop talks on the use and caveats to COVID-19 vaccination in patients with rheumatic disease and taking biologic and DMARD therapies. https://t.co/EJL6hVLnrp https://t.co/xkCRRHtkV9
Dr. John Cush RheumNow( View Tweet)
3 weeks ago
#BestACR20Tweets Cohort study from NYC shows that patients w/COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressive https://t.co/9mnb05Xqfa

Dr. John Cush RheumNow( View Tweet)

3 weeks ago
#BestACR20Tweets Racial/ethnic minorities with rheum Dz(RD) & COVID had increased odds of hospitalization & vent support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital https://t.co/Aa5UHwvXTA https://t.co/cFk8z8p985
Dr. John Cush RheumNow( View Tweet)
3 weeks 1 day ago
#BestACR20Tweets RT @KDAO2011 : Abstr#0013 TEASER! Colchicine may improve COVID19 outcomes in hospitalized patients. 50 pts 1:1 colchicine vs. PCB + standard of care: Colchicine group 2X more likely to be d/c from hospital, and less likely to die. Larger studies needed! #ACR20

Dr. John Cush RheumNow( View Tweet)

3 weeks 4 days ago
#Bestof2020: Rheumatic Disease Drugs and COVID-19 https://t.co/82uGbNqm9R https://t.co/U0WyTL5kYZ
Dr. John Cush RheumNow( View Tweet)
3 weeks 5 days ago
#BestACR20Tweets RT @jeffsparks :Important results from @kmdsilvaMD (newly funded by @RheumResearch): rheumatic patients with COVID with higher risk of hospitalization, ICU admission, CHF, AKI, and VTE than matched comparators. @zach_wallace_md https://t.co/bmuPBf89xD https://t.co/njHYkbenjy
Dr. John Cush RheumNow( View Tweet)
3 weeks 6 days ago
×